Advanced therapeutic solutions should be proposed to insulin-dependent CF patients by diabetologists experts in technological field, along with a close follow-up by a specialized multidisciplinary team with expertise in diabetes and CF; this approach can lead to a larger use of these advanced tools, an improvement of glycemic control and a low discontinuation rate in CF patients (39). This evidence concerns the gene INS and cystic fibrosis.